Johnson & Johnson and Roche are reportedly in talks with China's Henlius Biotech over rights to HLX43, an experimental cancer drug in mid-stage trials. A deal could fetch Henlius hundreds of millions, though negotiations remain uncertain. The talks come as US regulators consider tighter scrutiny of Chinese-developed medicines and licensing deals.